High level of interleukin-10 in serum after therapy is characteristic of prostate carcinoma patients with high Gleason score, high tumor volume and present peritumoral infiltration

Dejan  Jovanović; Vladimir Bančević; Vanja Jovanović; Gordana Šupić; Džihan Abazović; Ivan Stanojević; Danilo Vojvodić

doi:10.2298/VSP190820117J

Dejan Jovanović Military Medical Academy, Institute of Radiology, Belgrade, Serbia
Vladimir Bančević Military Medical Academy, Clinic for Urology, Belgrade, Serbia
Vanja Jovanović Health Center New Belgrade - General Practice, Belgrade, Serbia
Gordana Šupić University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
Džihan Abazović Emergency Medical Center of Montenegro, Podgorica, Montenegro
Ivan Stanojević University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
Danilo Vojvodić University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP190820117J

Keywords: interleukin-10;, interleukins;, neoplasm grading;, prostate neoplasms;, prostatic hyperplasia.

Abstract

Background/Aim. Recent data imply the significance of certain cytokines in the appearance and development of prostate cancer (PC), as well as their association with pathohistological and/or clinical characteristics of PC. The aim of this study was to examine the relationship between the IL-10 concentration with histopathological and clinical characteristics of PC patients. Methods. IL-10 concentration was determined in serum, urine and prostate massage secret (pms) samples of 88 CP patients (initially and after therapy), 20 benign prostatic hyperplasia (BPH) patients and 15 healthy controls. Results. Compared to BPH and control groups, PC patients had the highest average serum IL-10 concentration. Interestingly, BPH patients demonstrated the highest concentration of IL-6 in urine and pms samples. Also, patients with G3 gradus and with the highest Gleason score (4 + 4) demonstrated the highest IL-10 serum level. PC patients without any histopathological sign of tumor invasion had a significantly increased serum IL-10, either before or after the therapy, compared to the patient group with evident invasion of tumor cells. The therapy induced different IL-10 profile in serum and urine samples. After the therapy, there was a clear significant IL-10 increase in serum of patients with unfavorable Gleason score (4 + 4), with present infiltration of tumor cells in peritumoral tissue (lymphatic, vascular and combined) and in patients with high tumor volume. Conclusion. PC patients without any histopathological signs of tumor invasion before the therapy have significantly increased serum IL-10 concentration compared to those with the signs of tumor invasion. There is a clear dissociation of IL-10 values between a serum sample and local, urine and pms samples from a particular patient. After the therapy, high IL-10 serum concentration is present only in patients with high Gleason score, present infiltration of peritumoral tissue and high tumor volume.

Author Biography

Dejan Jovanović, Military Medical Academy, Institute of Radiology, Belgrade, Serbia

potpukovnik dr Dejan Jovanović, načelnik Odeljenja Radioterapije , Instituta za radiologiju VMA

References

Patel AR, Klein EA. Risk factors for prostate cancer. Nat Clin Pract Urol 2009; 6(2): 87–95.

Ricote M, Garcia-Tuñon F, Bethencourt, M. Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer 2004; 100: 1388‒96.

Tazaki E, Shimizu N, Tanaka R, Yoshizumi M, Kamma H, Imoto S, et al. Serum cytokine profiles in patients with prostate car-cinoma. Exp Ther Med 2011; 2(5): 887‒91.

Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117(5): 1175–83.

de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6(1): 24‒37.

Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007; 117(5): 1137‒46.

Tindall EA, Severi G, Hoang HN, Ma CS, Fernandez P, Southey MC, et al. Australian Prostate Cancer BioResource. Compre-hensive analysis of the cytokine-rich chromosome 5q31.1 re-gion suggests a role for IL-4 gene variants in prostate cancer risk. Carcinogenesis 2010; 31(10): 1748‒54.

Xu H, Hu MB, Bai PD, Zhu WH, Liu SH, Hou JY, et al. Proin-flammatory cytokines in prostate cancer development and progression promoted by high-fat diet. Biomed Res Int 2015; 2015: 249741.

Christensen E, Pintilie M, Evans KR, Lenarduzzi M, Ménard C, Catton CN, et al. Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity. Clin Cancer Res 2009; 15(17): 5576‒83.

Mahon KL, Lin HM, Castillo L, Lee BY, Lee-Ng M, Chatfield MD, et al. Cytokine profiling of docetaxel-resistant castra-tion-resistant prostate cancer. Br J Cancer 2015; 112(8): 1340‒8.

Fujita K, Ewing CM, Isaacs WB, Pavlovich CP. Immunomodula-tory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. Int J Cancer 2011; 129(2): 424‒32.

Cerović S, Brajušković G, Vukotić V. Premalignant lesions and prostate cancer. Belgrade: IP Beograd d.o.o; 2009. (Serbian)

Brierley J, Gospodarowicz MK, Wittekind C. 8th Edition of the UICC TNM classification of Malignant Tumors [published 2016 December 1]. Available from: https://www.uicc.org/news/8th-edition-uicc-tnm-classification-malignant-tumors-published

Vignozzi L, Cellai I, Santi R, Lombardelli L, Morelli A, Comeglio P et al. Antiinflammatory effect of androgen receptor activa-tion in human benign prostatic hyperplasia cells. J Endocrinol 2012; 214(1): 31‒43.

Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the inter-leukin-10 gene promoter. Eur J Immunogenet 1997; 24(1): 1‒8.

Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A 1998; 95(16): 9465‒70.

Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED, et al. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 2006; 66(8): 4525‒30.

Eder T, Mayer R, Langsenlehner U, Renner W, Krippl P, Wascher TC, et al. Interleukin-10 [ATA] promoter haplotype and pros-tate cancer risk: A population-based study. Eur J Cancer 2007; 43(3): 472–5.

Zou YF, Wang F, Feng XL, Tian YH, Tao JH, Pan FM, Huang F. Lack of association of IL-10 gene polymorphisms with prostate cancer: evidence from 11,581 subjects. Eur J Cancer 2011; 47(7): 1072‒9.

Shao N, Xu B, Mi YY, Hua LX. IL-10 polymorphisms and prostate cancer risk: a meta-analysis. Prostate Cancer Prostatic Dis 2011; 14(2): 129‒35.

Kwon EM, Salinas CA, Kolb S, Fu R, Feng Z, Stanford JL, et al. Genetic polymorphisms in inflammation pathway genes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2011; 20(5): 923‒33.

Kazma R, Mefford JA, Cheng I, Plummer SJ, Levin AM, Rybicki BA, et al. Association of the Innate Immunity and Inflamma-tion Pathway with Advanced Prostate Cancer Risk. PLoS ONE 2012; 7(12): e51680.

Yu Z, Liu Q, Huang C, Wu M, Li G. The interleukin 10 -819C/T polymorphism and cancer risk: a HuGE review and meta-analysis of 73 studies including 15,942 cases and 22,336 controls. OMICS 2013; 17(4): 200‒14.

Winchester DA, Gurel B, Till C, Goodman PJ, Tangen CM, Santel-la RM, et al. Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial. Prostate 2016; 76(6): 565‒74.

McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002; 62(12): 3369–72.

Faupel-Badger JM, Kidd LC, Albanes D, Virtamo J, Woodson K, Tangrea JA. Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control 2008, 19(2): 119-24.

Zabaleta J, Lin HY, Sierra RA, Hall MC, Clark PE, Sartor OA, et al. Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis 2008; 29(3): 573–8.

Zabaleta J, Su LJ, Lin HY, Sierra RA, Hall MC, Sartor AO, et al. Cytokine genetic polymorphisms and prostate cancer ag-gressiveness. Carcinogenesis 2009; 30(8): 1358‒62.

Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, Grinberg V, et al. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate 2009; 69(8): 874‒85.

Kesarwani P, Ahirwar DK, Mandhani A, Singh AN, Dalela D, Srivastava AN, et al. IL-10 -1082 G>A: a risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort. World J Urol 2009; 27(3): 389‒96.

Dluzniewski PJ, Wang MH, Zheng SL, De Marzo AM, Drake CG, Fedor HL, et al. Variation in IL10 and other genes in-volved in the immune response and in oxidation and prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev 2012; 21(10): 1774‒82.

Ianni M, Porcellini E, Carbone I, Potenzoni M, Pieri AM, Pas-tizzaro CD, et al. Genetic factors regulating inflammation and DNA methylation associated with prostate cancer. Prostate Cancer Prostatic Dis 2013; 16(1): 56‒61.

Eeles R, Goh C, Castro E, Bancroft E, Guy M, Al Olama AA, et al. The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol 2014; 11(1): 18‒31.

Shi X, Xie X, Xun X, Jia Y, Li S. Associations of IL-10 genet-ic polymorphisms with the risk of urologic cancer: a meta-analysis based on 18,415 subjects. Springerplus 2016; 5(1): 2034.

Chen H, Tang J, Shen N, Ren K. Interleukin 10 gene rs1800896 polymorphism is associated with the risk of prostate cancer. Oncotarget 2017; 8(39): 66204‒14.

Men T, Yu C, Wang D, Liu F, Li J, Qi X, et al. The impact of interleukin-10 (IL-10) gene 4 polymorphisms on peripheral blood IL-10 variation and prostate cancer risk based on pub-lished studies. Oncotarget 2017; 8(28): 45994‒6005.

Horvat V, Mandić S, Marczi S, Mrčela M, Galić J. Association of IL-1β and IL-10 Polymorphisms with Prostate Cancer Risk and Grade of Disease in Eastern Croatian Population. Coll Antropol 2015; 39(2): 393‒400.

Stearns ME, Rhim J, Wang M. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and in-hibition of matrix metalloproteinase (MMP)-2/MMP-9 secre-tion. Clin Cancer Res 1999; 5(1): 189‒96.

Liu J, Song B, Bai X, Liu W, Li Z, Wang J, et al. Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese. BMC Cancer 2010; 10: 456.

Cardillo MR, Ippoliti F. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis. Anticancer Res 2006; 26(5A): 3409‒16.

Hu W, Qian Y, Yu F, Liu W, Wu Y, Fang X, Hao W. Alterna-tively activated macrophages are associated with metastasis and poor prognosis in prostate adenocarcinoma. Oncol Lett 2015; 10(3): 1390‒6.

Itakura E, Huang RR, Wen DR, Paul E, Wünsch PH, Cochran AJ. IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Mod Pathol 2011; 24(6): 801‒9.

Zhen Z, Guo X, Liao R, Yang K, Ye L, You Z. Involvement of IL-10 and TGF-β in HLA-E-mediated neuroblastoma migra-tion and invasion. Oncotarget 2016; 7(28): 44340‒9.

Li L, Sun P, Zhang C, Li Z, Zhou W. MiR-98 suppresses the ef-fects of tumor-associated macrophages on promoting migra-tion and invasion of hepatocellular carcinoma cells by regulat-ing IL-10. Biochimie 2018; 150: 23‒30.

Wang R, Lu M, Zhang J, Chen S, Luo X, Qin Y, Chen H. In-creased IL-10 mRNA expression in tumor-associated macro-phage correlated with late stage of lung cancer. J Exp Clin Cancer Res 2011; 30: 62.

Ahmad N, Ammar A, Storr SJ, Green AR, Rakha E, Ellis IO, et al. IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients. Cancer Immunol Immu-nother 2018; 67(4): 537‒49.

Stearns ME, Wang M. Antimestatic and antitumor activities of interleukin 10 in transfected human prostate PC-3 ML clones: Orthotopic growth in severe combined immunodeficient mice. Clin Cancer Res 1998; 4(9): 2257‒63.

Yu D, Zhong Y, Li X, Li Y, Li X, Cao J, et al. ILs-3, 6 and 11 increase, but ILs-10 and 24 decrease stemness of human pros-tate cancer cells in vitro. Oncotarget 2015; 6(40): 42687‒703.

Dwivedi S, Goel A, Natu SM, Mandhani A, Khattri S, Pant KK. Diagnostic and prognostic significance of prostate specific an-tigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study. Asian Pac J Cancer Prev 2011; 12(7): 1843‒8.